Remove Acquisitions Remove IPO Remove Pharmaceutical
article thumbnail

How Common are Postmerger Divestitures of Acquired Company Units?

M&A Leadership Council

Few companies divest units immediately following an acquisition (unless they are compelled to do so by antitrust regulators), but many companies divest them eventually. In any given year, nearly half of the acquisitions that occur come about because the sellers are divesting a company unit. What is a split-up?

article thumbnail

Cooley’s 2023 Life Sciences M&A Year in Review: Potent Mix of Creativity and Resilience Spurs Activity Heading Into 2024

Cooley M&A

While the year saw an overall decline in M&A activity (down 17% from 2022) , total pharmaceuticals and life sciences deal value in 2023 increased by approximately 50% compared to 2022. billion; Bristol Myer Squibb’s acquisition of RayzeBio for $4.1 billion; and Roche’s acquisition of Carmot Therapeutics for up to $3.1

M&A 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cooley’s 2022 Life Sciences M&A Year in Review

Cooley M&A

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions.

M&A 40
article thumbnail

Shareholders vs. Stakeholders - Understanding Corporate Responsibilities

Peak Frameworks

For example, in the 2012 Facebook IPO, common shareholders gained exposure to the tech giant's fortunes, while also securing a say in corporate matters. For example, during the acquisition of Dell by Silver Lake Partners in 2013, understanding the shareholders' interests was paramount to offering the right price and terms.

article thumbnail

Cooley’s 2020 Life Sciences M&A Year in Review

Cooley M&A

The second half of the year witnessed a rebound spurred by several multibillion-dollar deals, including Gilead’s acquisition of Immunomedics for nearly $21 billion and AstraZeneca’s proposed acquisition of Alexion Pharmaceuticals for $39 billion. Life Sciences Enters the SPAC Party, But Will Reverse Merger Suitors Join In?

M&A 40
article thumbnail

Spot Cyber & IT Challenges Through Improved Due Diligence

M&A Leadership Council

For example, we supported a carve-out acquisition for a Fortune 50 energy sector client recently, where the business to be carved out was the large, regional field operation that stretched across half of the United States, but no IT assets and no IT people were initially included in the asset list.

IT 52
article thumbnail

Spot Cyber & IT Challenges

M&A Leadership Council

For example, we supported a carve-out acquisition for a Fortune 50 energy sector client recently, where the business to be carved out was the large, regional field operation that stretched across half of the United States, but no IT assets and no IT people were initially included in the asset list.

IT 52